CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aileron Therapeutics, Inc. a clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary Stapled Peptide drug platform, today announced that Joseph Yanchik III, Chief Executive Officer of Aileron Therapeutics, will present at the Leerink Global Healthcare Conference on Wednesday, February 12th at 11:30a.m. EST at the Waldorf Astoria Hotel in New York.
About Stapled Peptides
Stapled Peptides are an emerging class of drugs with a unique set of properties that fully capitalize on 25 years of genetic research to attack the critical drivers of complex diseases, including cancer, endocrine/metabolic disorders and inflammation. Aileron’s proprietary Stapled Peptide drug platform locks peptides into their biologically active shape and imparts unprecedented pharmaceutical stability within the body. Stapled Peptide drugs are derived from natural peptides and are designed to potently and specifically target protein-protein interactions both inside and outside the cell. This new class of drugs represents a fundamentally new therapeutic approach to modulate signaling pathways to treat human disease.
About Aileron Therapeutics
Aileron Therapeutics is a clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary Stapled Peptide drug platform. With its proprietary Stapled Peptide platform, Aileron aims to dramatically improve the treatment of a wide range of diseases – including cancer and metabolic and endocrine conditions – and positively impact the lives of millions of patients. Aileron’s lead drug development programs are its p53 re-activator for the treatment of cancer, ALRN-6924, and ALRN-5281, a long-acting, growth hormone releasing factor (GRF) for adult growth hormone deficiency that completed a Phase 1 clinical trial in 2013. For more information, please visit www.aileronrx.com.